Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3
The experimentally established mechanism targets of Epinephrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 7/20 | 1.00 |
| ▸ | ADRB1 known ✓ | P08588 | 6/20 | 1.00 |
| ▸ | ADRB3 known ✓ | P13945 | 5/20 | 1.00 |
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 1.00 |
| ▸ | ADRA2B known ✓ | P18089 | 3/20 | 1.00 |
| ▸ | ADRA2C known ✓ | P18825 | 3/20 | 1.00 |
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 1.00 |
| ▸ | ADRA1B known ✓ | P35368 | 3/20 | 1.00 |
| ▸ | ADRA1D known ✓ | P25100 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 1.00 |
| ▸ | TSHR | P16473 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | MTOR | P42345 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Racepinephrine SCHEMBL29396039 | 1.00 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT | |
| Racepinephrine SCHEMBL3815 | 1.00 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT | |
| Epinephrine SCHEMBL29353423 | 1.00 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT | |
| [11C]Epinephrine SCHEMBL29374823 | 1.00 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT | |
| L-Adrenaline SCHEMBL11647 | 1.00 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT | |
| [11C]Epinephrine SCHEMBL29371663 | 1.00 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT | |
| L-Adrenaline SCHEMBL29519331 | 1.00 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT | |
| Racepinephrine SCHEMBL11631789 | 1.00 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT | |
| Racepinephrine SCHEMBL20493843 | 1.00 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT | |
| Epinephrine SCHEMBL8576894 | 1.00 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11904317-B2 | Microfluidic method for single cell analysis | HIFIBIO SAS (FR) | 2024-02-20 | — | — | US | claimed |
| US-20210371403-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS INC. | 2021-12-02 | — | — | US | claimed |
| EP-3912981-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2021-11-24 | — | — | EP | claimed |
| US-20210300898-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS INC. | 2021-09-30 | — | — | US | claimed |
| US-20210146366-A1 | MICROFLUIDIC METHOD FOR SINGLE CELL ANALYSIS | HIFIBIO SAS (FR) | 2021-05-20 | — | — | US | claimed |
| EP-3781315-A1 | MICROFLUIDIC METHOD FOR SINGLE CELL ANALYSIS | HiFiBiO SAS (FR) | 2021-02-24 | — | — | EP | claimed |
| WO-2020061476-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS, INC. (US) | 2020-03-26 | — | — | WO | claimed |
| WO-2020061473-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS, INC. (US) | 2020-03-26 | — | — | WO | claimed |
| WO-2019202135-A1 | MICROFLUIDIC METHOD FOR SINGLE CELL ANALYSIS | HIFIBIO SAS (FR) | 2019-10-24 | — | — | WO | claimed |
| EP-3556466-A1 | MICROFLUIDIC METHOD FOR SINGLE CELL ANALYSIS | HiFiBiO SAS (FR) | 2019-10-23 | — | — | EP | claimed |
| US-10039728-B1 | More potent and less toxic formulations of epinephrine and methods of medical use | RUBIN, DARREN | 2018-08-07 | — | — | US | claimed |
| EP-3193611-A2 | MK2 INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2017-07-26 | — | — | EP | claimed |
| WO-2016044463-A2 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-03-24 | — | — | WO | claimed |
| WO-2024125464-A1 | TETRAHYDROISOQUINOLIN-ONE DERIVATIVES, PREPARATION METHODS AND MEDICINAL USES THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024125451-A1 | PIPERINDIN-ONES DERIVATIVES, PREPARATION METHODS AND MEDICINAL USES THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-06-20 | — | — | WO | disclosed |
| US-20240190890-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2024-06-13 | — | — | US | disclosed |
| EP-0002624-A1 | 2-Benzazepine compounds, processes for their preparation and pharmaceutical compositions containing them | SMITHKLINE BECKMAN CORPORATION (US) | 1979-06-27 | — | — | EP | disclosed |
| EP-0001002-A1 | Indanamines, processes for their preparation and compositions containing them | SMITHKLINE BECKMAN CORPORATION (US) | 1979-03-07 | — | — | EP | disclosed |
| US-4128666-A | PHENYLETHANOLAMINE N-METHYL-TRANSFERASE INHIBITORS | SMITHKLINE CORPORATION (US) | 1978-12-05 | — | — | US | disclosed |
| US-4079140-A | BLOOD PLAQUE AGGREGATION INHIBITORS, SPASMOLYTIC, ANALGESIC, ANTIINFLAMMATORY, VASODILATORS | INNOTHERA (FR) | 1978-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300898-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | SNRPE, G3BP1, G3BP2 | ADRB2 4647/4885ADRB1 4656/4885ADRB3 4482/4885 |
| US-20210371403-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | SNRPE, G3BP1, G3BP2 | ADRB2 4647/4885ADRB1 4656/4885ADRB3 4482/4885 |
| US-20240190890-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, CSNK1G2, CSNK2A2 | ADRB2 2083/4885ADRB1 3810/4885ADRB3 3958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.